Beyond the Hype: The Real Impact of AI in Techbio

​AI promises to reshape how we discover drugs, design therapies, and accelerate innovation in techbio. But promises aren’t products. This event brings together two complementary conversations:

• ​Founder Panel: The builders’ perspective. How are founders actually applying AI in their companies today? What challenges are they facing in data, adoption, and scientific validation? Where are they finding real traction versus inflated claims?

  • ​Jennifer Dionne - CEO, Pumpkinseed Bio

  • ​Yogev Debbi - CEO, Mana.bio

  • ​Jason Steiner - Stealth NewCo

  • ​Sylvain Gariel - Stealth NewCo

  • ​Anastasia Budinskaya - NFX - Moderator

• ​Investor Panel: The capital perspective. How do investors assess the AI wave in techbio? What signals separate durable companies from hype cycles? How should capital be allocated to balance vision with reality?

  • ​Chris Ghadban - The Venture Collective

  • ​Dana Watt - Breakout Ventures

  • ​Elliot Hershberg - Amplify

  • ​Tim Luker - Lilly Ventures

  • ​Omri Amirav-Drory - NFX - Moderator

​Together, these discussions will explore where AI is genuinely creating value, what hurdles remain, and how to navigate the line between bold vision and overblown hype.